Mika Skeppholm

Publications
CV
Public outreach and news

Articles

Journal article: BIOMEDICINE & PHARMACOTHERAPY. 2024;180:117613
Apixaban trough concentrations in atrial fibrillation patients with reduced renal function.
Al-Aieshy F; Skeppholm M; Fyrestam J; Johansson F; Pohanka A; Malmström RE
Article: TH OPEN. 2022;06(03):e238-e247
Rapid Detection of Apixaban by a ROTEM-Based Approach and Reversibility with Andexanet Alfa or DOAC-Stop
Taune V; Skeppholm M; Agren A; Wikman A; Hillarp A; Wallen H
Article: JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 2018;16(12):2462-2470
Rapid determination of anticoagulating effects of dabigatran in whole blood with rotational thromboelastometry and a thrombin-based trigger
Taune V; Skeppholm M; Agren A; Gryfelt G; Malmstrom RE; Wikman A; Van Ryn J; Wallen H
Article: THROMBOSIS AND HAEMOSTASIS. 2017;117(9):1700-1704
Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting
Antovic A; Norberg E-M; Berndtsson M; Rasmuson A; Malmstrom RE; Skeppholm M; Antovic J
Article: THROMBOSIS RESEARCH. 2017;153:76-82
Whole blood coagulation assays ROTEM and T-TAS to monitor dabigatran treatment
Taune V; Wallen H; Agren A; Gryfelt G; Sjovik C; Wintler AM; Malmstrom RE; Wikman A; Skeppholm M
Article: THROMBOSIS AND HAEMOSTASIS. 2016;116(6):1131-1139
Usefulness of Health Registers for detection of bleeding events in outcome studies
Friberg L; Skeppholm M
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2016;72(6):671-679
Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation
Al-Aieshy F; Malmstrom RE; Antovic J; Pohanka A; Ronquist-Nii Y; Berndtsson M; Al-Khalili F; Skeppholm M
Article: JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 2016;14(5):1043-1053
A single test to assay warfarin, dabigatran, rivaroxaban, apixaban, unfractionated heparin, and enoxaparin in plasma
Letertre LR; Gudmundsdottir BR; Francis CW; Gosselin RC; Skeppholm M; Malmstrom RE; Moll S; Hawes E; Francart S; Onundarson PT
Article: THROMBOSIS RESEARCH. 2015;136(1):148-153
Clinical evaluation of laboratory methods tomonitor apixaban treatment in patients with atrial fibrillation
Skeppholm M; Al-Aieshy F; Berndtsson M; Al-Khalili F; Ronquist-Nii Y; Soderblom L; Ostlund AY; Pohanka A; Antovic J; Malmstrom RE
Article: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2015;65(3):225-232
Benefit of Anticoagulation Unlikely in Patients With Atrial Fibrillation and a CHA₂DS₂-VASc Score of 1
Friberg L; Skeppholm M; Terent A
Article: CLINICAL RESEARCH IN CARDIOLOGY. 2014;103(12):998-1005
Adherence to warfarin treatment among patients with atrial fibrillation
Skeppholm M; Friberg L
Article: THROMBOSIS RESEARCH. 2014;134(4):783-789
On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation
Skeppholm M; Hjemdahl P; Antovic JP; Muhrbeck J; Eintrei J; Ronquist-Nii Y; Pohanka A; Beck O; Malmstrom RE
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2013;69(11):1875-1881
Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma
Antovic JP; Skeppholm M; Eintrei J; Boija EE; Soderblom L; Norberg E-M; Onelov L; Ronquist-Nii Y; Pohanka A; Beck O; Hjemdahl P; Malmstrom RE
Article: ANGIOLOGY. 2012;63(7):500-503
Risk Factors for Myocardial Infarction With Normal Coronary Arteries and Myocarditis Compared With Myocardial Infarction With Coronary Artery Stenosis
Agewall S; Daniel M; Eurenius L; Ekenback C; Skeppholm M; Malmqvist K; Hofman-Bang C; Collste O; Frick M; Henareh L; Jernberg T; Tornvall P
Article: THROMBOSIS AND HAEMOSTASIS. 2012;107(6):1122-1129
Platelet-derived microparticles during and after acute coronary syndrome
Skeppholm M; Mobarrez F; Malmqvist K; Wallen H
Article: THROMBOSIS RESEARCH. 2011;128(5):483-489
Is fibrin formation and thrombin generation increased during and after an acute coronary syndrome?
Skeppholm M; Kallner A; Malmqvist K; Blomback M; Wallen H
Article: BLOOD COAGULATION AND FIBRINOLYSIS. 2009;20(8):619-626
ADAMTS13 and von Willebrand factor concentrations in patients with diabetes mellitus
Skeppholm M; Kallner A; Kalani M; Jorneskog G; Blomback M; Wallen HN
Article: CLINICAL CHEMISTRY AND LABORATORY MEDICINE. 2008;46(8):1175-1179
Can both EDTA and citrate plasma samples be used in measurements of fibrinogen and C-reactive protein concentrations?
Skeppholm M; Wallen NH; Blomback M; Kallner A
Article: THROMBOSIS AND HAEMOSTASIS. 2007;98(4):871-882
A global assay of haemostasis which uses recombinant tissue factor and tissue-type plasminogen activator to measure the rate of fibrin formation and fibrin degradation in plasma
He S; Zhu K; Skeppholm M; Vedin J; Svensson J; Egberg N; Blomback M; Wallen H
Article: THROMBOSIS RESEARCH. 2007;121(2):175-181
Comparison of two immunochemical assays for measuring thrombin-activatable fibrinolysis inhibitor concentration with a functional assay in patients with acute coronary syndrome
Skeppholm M; Wallen NH; Malmqvist K; Kallner A; Antovic JP

All other publications

Thesis / dissertation: 2011
Studies of haemostasis in acute coronary syndromes and diabetes mellitus
Skeppholm, Mika
Letter: BLOOD COAGULATION AND FIBRINOLYSIS. 2009;20(7):611-613
Inflammation and thrombin generation cause increased thrombin activatable fibrinolysis inhibitor levels in experimental human endotoxemia
Skeppholm M; Wallen NH; Mobarrez F; Sollevi A; Soop A; Antovic JP
Review: LAKARTIDNINGEN. 2007;104(37):2586-2588
[Myocardial infarction with normal coronary arteries in women. MINCA--a specific type of myocardial infarction].
Skeppholm M; Agewall S; Ljungman P; Daniel M; Eriksson M; Hofman-Bang C; Malmqvist K; Reistam U; Svane B; Tornvall P

Employments

Affiliated to Research, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, 2022-2025

Degrees and Education

Degree Of Doctor Of Philosophy, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, 2011
University Medical Degree, Karolinska Institutet, 1996

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI